Digital Rectal Examination (DRE): Purpose, Procedure, and Guideline Recommendations

Purpose and Procedure of Digital Rectal Examination

The digital rectal examination (DRE) is a clinical examination procedure used to assess the prostate gland in men, evaluate rectal abnormalities, and screen for potential cancers, with the American Urological Association (AUA) recommending DRE as part of the physical examination for patients with suspected benign prostatic hyperplasia 1
DRE serves as a physical examination technique to assess the prostate gland, rectum, and surrounding structures, as recommended by the American Cancer Society and the American College of Physicians (ACP) 1, 2
When evaluating the prostate, DRE helps detect subtle abnormalities including changes in symmetry, consistency, induration, or nodules that may suggest prostate cancer, with a study finding that DRE had a true-positive detection rate, although the exact rate is not specified in the provided citations 3, 4
For prostate examination specifically, the examiner evaluates size, symmetry of the two lobes, consistency, and presence of nodules, induration, or asymmetry, with the American Cancer Society recommending DRE as part of prostate cancer screening beginning at age 50 for average-risk men 1, 2, 3, 4

Role in Prostate Cancer Screening and Guideline Recommendations

The American Cancer Society recommends DRE as part of prostate cancer screening beginning at age 50 for average-risk men, and at a younger age for high-risk groups including African Americans and those with strong family history 3, 4
The American College of Physicians (ACP) includes DRE in their guidance statement on prostate cancer screening but notes its limitations, with the National Comprehensive Cancer Network (NCCN) recommending baseline DRE for men aged 50-70 years as part of early detection evaluation 5, 6, 7, 8
The American Urological Association (AUA) recommends DRE as part of the physical examination for patients with suspected benign prostatic hyperplasia, and DRE should be performed by healthcare workers skilled in detecting subtle abnormalities of the prostate and rectum 1, 3, 4

Best Practice Recommendations

DRE should be performed by healthcare workers skilled in detecting subtle abnormalities of the prostate and rectum, and for prostate cancer screening, DRE should not be used as a stand-alone test but should be performed in conjunction with serum PSA measurement 2, 3, 4
Clinicians should be aware that DRE tends to underestimate prostate size; if the prostate feels large by DRE, it is usually found to be enlarged by ultrasound or other measurement techniques, as noted by the American Urological Association (AUA) 1

Prostate Cancer Screening Recommendations

Guideline Positions on Digital Rectal Examination (DRE)

The American Cancer Society recommends that PSA and DRE should be offered annually beginning at age 50 to men with at least 10-year life expectancy, but explicitly states that "in men for whom DRE is an obstacle to testing, PSA alone is an acceptable alternative" 9, 10, 11
The American College of Physicians includes DRE in their guidance but notes that "the PSA test is more sensitive than DRE, and no screening trials have evaluated the utility of DRE alone" 12
The U.S. Preventive Services Task Force concluded there was insufficient evidence to recommend for or against routine screening with either PSA or DRE 13
The American Cancer Society suggests considering adding DRE only if the patient specifically requests it, the clinician is skilled in prostate examination, and it will not serve as a barrier to PSA-based screening 9
The American College of Physicians advises against continuing DRE screening in men over age 70 or with life expectancy less than 10-15 years, as harms clearly outweigh any potential benefits 12

Screening Approach

The American Cancer Society recommends engaging in structured shared decision-making explaining that PSA screening prevents approximately 1-2 deaths per 1,000 men screened over 13 years, but causes overdiagnosis in 29-44% of detected cancers, and considering adding DRE as part of this discussion 14

Prostate Cancer Screening Guidelines

Evidence Against Routine DRE Screening

No randomized controlled trials have demonstrated that regular DRE screening reduces mortality from prostate cancer, despite decades of use, as reported by the American family physician 15, 16
The majority of studies on DRE have been observational with varying measures of sensitivity and survival, but none have shown a mortality reduction, according to the American family physician 17

Current Guideline Recommendations

The U.S. Preventive Services Task Force (USPSTF) and Canadian Task Force on Preventive Health Care do not recommend routine DRE or PSA screening for asymptomatic men, citing insufficient evidence, as stated by the Annals of Internal Medicine and American family physician 15, 18, 19
Even for men with family history of prostate cancer, guidelines recommend PSA-based screening with shared decision-making starting at age 45, not routine DRE, according to Ca-A Cancer Journal for Clinicians and American family physician 15, 20, 21

Clinical Algorithm for Men Over 50 with Family History

Men with two or more first-degree relatives with prostate cancer are considered high-risk and should begin screening discussions at age 45, as recommended by Ca-A Cancer Journal for Clinicians and American family physician 15, 20
Offer annual or biennial PSA testing as the primary screening modality, according to Ca-A Cancer Journal for Clinicians 20

Digital Rectal Examination Guidelines for Adult Males

Screening Recommendations by Risk Category

The American College of Physicians recommends that DRE should be offered as part of an informed decision-making process alongside PSA testing for men aged 50 and older who have at least a 10-year life expectancy 22, 23
Informed discussions about prostate cancer screening should begin at age 50 for men with at least 10-year life expectancy, according to the American Academy of Family Physicians 24, 22
The American Academy of Family Physicians and the American College of Physicians recommend that screening discussions should begin at age 45 for African American men and those with a first-degree relative diagnosed before age 65 24, 22, 23
Men with two or more first-degree relatives diagnosed before age 65 should begin screening discussions at age 40, as recommended by the American Academy of Family Physicians and the American College of Physicians 24, 23

Practical Implementation

The American Academy of Family Physicians recommends that in-office single-panel guaiac FOBT using stool collected during DRE is not recommended for colorectal cancer screening due to low sensitivity 24

Prostate Cancer Screening Guidelines

Introduction to Screening Recommendations

The American Cancer Society recommends that men with average risk, such as this patient, begin screening discussions at age 50, not 45 25, 26, 27, 28
High-risk criteria requiring earlier screening include African American race or a first-degree relative diagnosed before age 65 years, which does not apply to this patient 25, 26, 27

Screening and Diagnosis

Men with average risk should begin screening discussions at age 50, and screening should include shared decision-making about PSA testing, discussing both benefits and harms 25, 26, 27, 28
The National Comprehensive Cancer Network recommends that PSA screening should not begin until age 50 in average-risk men, and this patient is only 45 28, 25, 26, 27
For men who choose screening, baseline PSA with or without DRE should be offered at age 50, and for men with PSA <2.5 ng/mL, screening intervals can be extended to every 2 years 26, 27

Recommendations for Patient Care

The American Cancer Society recommends providing reassurance that a normal DRE is encouraging and that family history does not place the patient in a high-risk category requiring immediate screening 25, 26, 27
The patient should be educated that screening discussions should begin at age 50 for average-risk men, and that immediate PSA testing would be appropriate only if he were African American, had a first-degree relative diagnosed before age 65, or had multiple family members diagnosed before age 65 25, 26, 27, 28